Accelerating global access to life-saving vaccines.

We apply rigorous science to build knowledge and support for the value of vaccines.

Updates

Beating the world’s deadliest disease against all odds

December 2018

When it comes to stopping childhood pneumonia, the odds are stacked against the poor and vulnerable; but vaccines can give them a fighting chance. In 2009, approximately 3,400 children died of pneumonia every day. Now, with investments in pneumonia prevention and treatment – including the introduction and scale up of two vaccines to prevent the most common causes of pneumonia death, Haemophilus influenzae type b and pneumococcus – that number has fallen to 1,000.

Press Release: Report finds inequity may slow progress in preventing child pneumonia and diarrhea deaths

November 2018

A new report finds health systems are falling woefully short of ensuring the most vulnerable children have sufficient access to prevention and treatment services in 15 countries that account for 70% of global pneumonia and diarrhea deaths in children under five.

Commentary: Pneumonia, Diarrhea, and Measles force Bangladeshi households to make difficult financial decisions when illnesses arise

October 2018

Few diseases have as much power to cause wide-ranging impact among the population as pneumonia, diarrhea, and measles. These three illnesses can cause long-term disability and can require a significant amount of care. In addition to the pain and the risk of death or disability, people experiencing these illnesses face economic consequences now rising like out-of-pocket expenditures.

Digital Tools

IVAC’s digital platforms contain downloadable vaccine introduction maps, messaging compendiums, advocacy guides, and more.

Where We Work

IVAC works with governments and major research institutions in 38 countries

What We Do: Project highlights

The Pneumonia Etiology Research for Child Health (PERCH) study

The Pneumonia Etiology Research for Child Health (PERCH) study is a case-control study led by IVAC that enrolled 4,232 cases and 5,325 controls between 2011-2014 at 9 sites in 7 countries (The Gambia, Mali, Kenya, Zambia, South Africa, Bangladesh and Thailand). Read More >

Rotavirus Accelerated Vaccine Introduction Network (RAVIN)

The Rotavirus Accelerated Vaccine Introduction Network (RAVIN) is a partnership led by Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC), in collaboration with JSI and CDC, and is designed to provide policy, advocacy, and technical support to focus countries throughout the entire continuum of introducing rotavirus vaccine (RVV) – from the consideration and decision-making process to implementation and post-launch activities. Read More >

More Highlights